Merck (MRK) Declares $0.45 Quarterly Dividend; 3.1% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Merck Announces Third-Quarter 2015 Dividend
May 26, 2015 1:31 PM EDTKENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.45 per share of the companys common stock for the third quarter of 2015. Payment will be made on July 8, 2015, to stockholders of record at the close of business on June 15, 2015.
About Merck
Todays Merck is a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription... More
SIMPONI® (golimumab) Gains Positive Opinion from Committee for Medicinal Products for Human Use (CHMP) for the Treatment of Non-Radiographic Axial Spondyloarthritis
May 26, 2015 6:34 AM EDTKENILWORTH, New Jersey, May 26, 2015 /PRNewswire/ --
MSD, known as Merck & Co., Inc. in the United States and Canada,- today announced that SIMPONI®(golimumab) has received CHMP positive opinion for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).[1] Once the EU commission issues their EC decision, and if approved, nr-axial SpA patients can be considered for the... More
